These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33408605)

  • 1. Zonisamide for the Treatment of Parkinson Disease: A Current Update.
    Li C; Xue L; Liu Y; Yang Z; Chi S; Xie A
    Front Neurosci; 2020; 14():574652. PubMed ID: 33408605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease.
    Grover ND; Limaye RP; Gokhale DV; Patil TR
    Indian J Pharmacol; 2013; 45(6):547-55. PubMed ID: 24347760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zonisamide in Parkinson's disease: a current update.
    Goel A; Sugumaran R; Narayan SK
    Neurol Sci; 2021 Oct; 42(10):4123-4129. PubMed ID: 34448999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
    Matsunaga S; Kishi T; Iwata N
    J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review.
    Kong L; Xi J; Jiang Z; Yu X; Liu H; Wang Z
    Biomed Res Int; 2022; 2022():4817488. PubMed ID: 36132085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.
    Murata M; Hasegawa K; Kanazawa I; Fukasaka J; Kochi K; Shimazu R;
    Mov Disord; 2015 Sep; 30(10):1343-50. PubMed ID: 26094993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zonisamide: in Parkinson's disease.
    Yang LP; Perry CM
    CNS Drugs; 2009 Aug; 23(8):703-11. PubMed ID: 19594199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zonisamide for the treatment of Parkinson's disease.
    Miwa H
    Expert Rev Neurother; 2007 Sep; 7(9):1077-83. PubMed ID: 17868006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
    Murata M
    Curr Pharm Des; 2004; 10(6):687-93. PubMed ID: 14965331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
    Fox SH; Katzenschlager R; Lim SY; Barton B; de Bie RMA; Seppi K; Coelho M; Sampaio C;
    Mov Disord; 2018 Aug; 33(8):1248-1266. PubMed ID: 29570866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
    Murata M; Hasegawa K; Kanazawa I;
    Neurology; 2007 Jan; 68(1):45-50. PubMed ID: 17200492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the use of zonisamide in Parkinson's disease.
    Bermejo PE; Anciones B
    Ther Adv Neurol Disord; 2009 Sep; 2(5):313-7. PubMed ID: 21180621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study on the Clinical Features of Parkinson's Disease With Probable Rapid Eye Movement Sleep Behavior Disorder.
    Long K; Wan C; Xiang Y; Liu J; Xu Q; Sun Q; Wang Z; Tian Y; Fang L; Yang Y; Yan X; Tang B; Guo J
    Front Neurol; 2020; 11():979. PubMed ID: 33041969
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy of Parkinson's disease--up to date].
    Murata M
    Rinsho Shinkeigaku; 2008 Nov; 48(11):986-8. PubMed ID: 19198140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.
    Cilia R; Cereda E; Akpalu A; Sarfo FS; Cham M; Laryea R; Obese V; Oppon K; Del Sorbo F; Bonvegna S; Zecchinelli AL; Pezzoli G
    Brain; 2020 Aug; 143(8):2490-2501. PubMed ID: 32844196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ropinirole: a review of its use in the management of Parkinson's disease.
    Matheson AJ; Spencer CM
    Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence.
    Bette S; Shpiner DS; Singer C; Moore H
    Ther Clin Risk Manag; 2018; 14():1737-1745. PubMed ID: 30271159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
    Pinter MM; Pogarell O; Oertel WH
    J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.